Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
akcea therapeutics
6
×
boston blog main
boston top stories
6
×
fda
6
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
biotech
clinical trials
inotersen
alnylam pharmaceuticals
boston
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
glaxosmithkline
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
national
nonalcoholic steatohepatitis
novartis
patisiran
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
tafamidis
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer immunotherapy
What
alnylam
fda
medicine
roundup
bio
cancer
drug
rna
rnai
uses
abbvie’s
according
afternoon
ago
ahead
akcea
allogene
alnylam’s
approve
approved
approves
awaits
biofourmis
biological
biotech
bucks
cases
celebrate
cells
centers
chance
cigarettes
control
corner
crispr
crossed
day
days
deaths
decades
Language
unset
Current search:
fda
×
" akcea therapeutics "
×
" boston top stories "
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision